About CRS

CRS has been described in the literature as an “unrecognized epidemic”.

We estimate that sinusitis, which includes both CRS and acute rhinosinusitis, impacts approximately 12% of the adult population in the United States, or approximately 30 million people, making it the fifth most common condition in people under the age of 65. Of this population, we estimate that approximately 14 million people are affected with CRS.

None of the current treatment options offer a sustained solution for CRS, including conventional steroids and sprays, as well as endoscopic sinus surgery.

Diagnosing CRS

Unmet Medical Need in CRS

The goals of therapy for CRS are to reduce mucosal swelling resulting from underlying inflammation, promote sinus drainage, and eradicate infections that may be present. The treatment of CRS is progressive in nature and typically begins with medical management, primarily with topical intranasal steroids and oral steroids. If this treatment is unsuccessful, an ENT physician may perform a sinus surgery.

Currently, there are no FDA-approved drug therapies for CRS for non-polyp patients, although some drugs approved for nasal polyps are used off-label in this population.

Back to Top